Combination Immunotherapy After ASCT for Multiple Myeloma (MM) Using MAGE-A3/Poly-ICLC Immunizations Followed by Vaccine-Primed and Activated Autologous T-Cells
Aaron P. Rapoport(University of Maryland, Baltimore), Carl H. June(University of Pennsylvania), Yinyan Xu(University of Pennsylvania), Kathleen Ruehle(University of Maryland, Baltimore), Nicole A. Aqui(University of Pennsylvania), Hong‐Bin Fang(University of Maryland, Baltimore), Kelly-Marie Betts(University of Maryland, Baltimore), Holly McConville(University of Pennsylvania), Ling Cai(The University of Texas Southwestern Medical Center), Scott E. Strome(Northwestern Medicine Lake Forest Hospital), Edward A. Stadtmauer(University of Pennsylvania), Bruce L. Levine(University of Pennsylvania), Dan T. Vogl(University of Pennsylvania), Sandra Westphal(University of Maryland, Baltimore), Anne Chew(Parker Institute for Cancer Immunotherapy), Saul Yanovich(Virginia Commonwealth University Medical Center), Ashraf Badros(University of Maryland, Baltimore), Görgün Akpek(Banner MD Anderson Cancer Center), Andres Μ. Salazar(Oncovir (United States)), Zhaohui Zheng(University of Pennsylvania), Elizabeth Veloso(University of Pennsylvania), Sunita Philip(University of Maryland, Baltimore), Brendan M. Weiss(Heidelberg University)
Cited by 5
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
|Nature Medicine|2002|5.1k
A human memory T cell subset with stem cell–like properties
|Nature Medicine|2011|2k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k